文献速递其他结缔组织病

靶向CD13/氨肽酶N作为硬皮病纤维化的新治疗策略

Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.
PubMed 文献 · Arthritis Rheumatol · 2024-09-18

本研究探讨靶向可溶性CD13(sCD13)-缓激肽受体B1(B1R)轴对系统性硬化症(SSc)纤维化的抑制作用。结果显示弥漫性皮肤型SSc皮肤中CD13、B1R和MMP14基因表达升高,B1R在COL8A1阳性肌成纤维细胞中表达最高,B1R拮抗剂可阻止sCD13或TGFβ的促纤维化反应,Cd13或Bdkrb1缺失小鼠对博来霉素诱导的皮肤纤维化和炎症抵抗。

要点

  • 弥漫性皮肤型SSc皮肤活检中CD13、B1R和MMP14基因表达升高。
  • B1R拮抗剂可阻止sCD13或TGFβ诱导的促纤维化反应。
  • Cd13或Bdkrb1缺失小鼠对博来霉素诱导的皮肤纤维化和炎症抵抗。

核心结论

  • 结果首次证明sCD13在SSc皮肤纤维化中起关键作用,提示靶向sCD13-B1R信号轴是SSc有前景的新治疗策略。

研究设计与样本

  • 检测SSc皮肤活检和分离的真皮成纤维细胞中CD13、B1R和MMP14的表达,并在体外和体内评估B1R拮抗剂抑制纤维化的效果。

主要发现

  • 弥漫性皮肤型SSc患者皮肤活检中CD13、B1R和MMP14基因表达升高。
  • SSc皮肤活检单细胞分析显示BDKRB1在COL8A1阳性肌成纤维细胞中表达最高,该细胞群仅见于SSc。
  • TGFβ诱导弥漫性皮肤型SSc皮肤成纤维细胞表达BDKRB1并产生sCD13。
  • sCD13处理弥漫性皮肤型SSc成纤维细胞促进纤维化基因表达、信号传导、细胞增殖、迁移和凝胶收缩。
  • B1R拮抗剂阻止sCD13或TGFβ的促纤维化反应;Cd13或Bdkrb1缺失小鼠对博来霉素诱导的皮肤纤维化和炎症抵抗,药物性B1R抑制具有相当抗纤维化效果。

临床怎么用

  • 作者认为靶向sCD13-B1R信号轴是SSc有前景的新治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune multisystem disease with poorly understood pathogenesis and ineffective treatment options. Soluble CD13 (sCD13), generated by the cleavage of cell surface CD13 via matrix metalloproteinase 14 (MMP14), signals through the bradykinin receptor B1 (B1R) to elicit pro-inflammatory, pro-arthritic, and pro-angiogenic responses. In this study, we explored the antifibrotic potential of targeting the sCD13-B1R axis in SSc. METHODS: The expression of CD13, B1R, and MMP14 was examined in SSc skin and explanted dermal fibroblasts. The efficacy of B1R antagonists in the inhibition on fibrosis was determined in vitro and in vivo. RESULTS: Expression of the genes for CD13, B1R, and MMP14 was elevated in skin biopsies from patients with diffuse cutaneous (dc) SSc. Notably, single-cell analysis of SSc skin biopsies revealed the highest BDKRB1 expression in COL8A1-positive myofibroblasts, a population exclusively seen in SSc. Transforming growth factor beta (TGFβ) induced the expression of BDKRB1 and production of sCD13 by dcSSc skin fibroblasts. Treatment of dcSSc fibroblasts with sCD13 promoted fibrotic gene expression, signaling, cell proliferation, migration, and gel contraction. The pro-fibrotic responses of sCD13 or TGFβ were prevented by a B1R antagonist. Mice lacking Cd13 or Bdkrb1 were resistant to bleomycin-induced skin fibrosis and inflammation. Pharmacological B1R inhibition had a comparable antifibrotic effect. CONCLUSION: These results are the first to demonstrate a key role for sCD13 in SSc skin fibrosis and suggest that targeting the sCD13-B1R signaling axis is a promising novel therapeutic approach for SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Muraoka S, Brodie WD, Mattichak MN, et al. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis Rheumatol. 2024. PMID: 39175116. doi:10.1002/art.42973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。